{"id":10772,"date":"2020-09-22T15:40:30","date_gmt":"2020-09-22T10:10:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10772"},"modified":"2023-04-04T11:59:12","modified_gmt":"2023-04-04T06:29:12","slug":"pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina","title":{"rendered":"Samsung\/AZ Deal; Gyroscope\u2019s Dry AMD Gene Therapy; Inflazome&#8217;s Buyout; Abbott\u2019s MitraClip4 EU Approval; Grail Buybacks"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a091e1990db9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a091e1990db9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\/#Samsung_Biologics_strikes_a_USD_3308_Mn_supply_deal_with_AstraZeneca\" >Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\/#Gyroscopes_gene_therapy_for_Dry_AMD_GT005_receives_USFDA_Fast_Track_Designation\" >Gyroscope\u2019s gene therapy for Dry AMD, GT005, receives USFDA Fast Track Designation&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\/#With_soaring_interest_in_inflammation_Roche_acquires_Inflazome_for_E380_M\" >With soaring interest in inflammation, Roche acquires Inflazome for \u20ac380 M<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\/#Abbotts_next-gen_MitraClip4_heart_valve_repair_device_nabs_EU_approval\" >Abbott\u2019s next-gen MitraClip4 heart valve repair device nabs EU approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\/#Illumina_to_pay_a_total_of_USD_8_Bn_to_reacquire_its_former_spinout_Grail\" >Illumina to pay a total of USD 8 Bn to reacquire its former spinout Grail<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-samsung-biologics-strikes-a-usd-330-8-mn-supply-deal-with-astrazeneca\"><span class=\"ez-toc-section\" id=\"Samsung_Biologics_strikes_a_USD_3308_Mn_supply_deal_with_AstraZeneca\"><\/span><strong>Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Samsung Biologics<\/strong> announced the conclusion of a long-term supply deal with <strong>AstraZeneca <\/strong>worth <strong>USD 330.8 Million<\/strong>.&nbsp;<\/p>\n\n\n\n<p>AZ has made several headlines the past few months, forming a slew of deals to manufacture and supply its products. Here, the company plans to leverage Samsung\u2019s expertise in developing effective, novel biopharmaceuticals to expand its foothold in biologics manufacturing in the Asia Pacific region.&nbsp;<\/p>\n\n\n\n<p>The deal struck shall help Asia Pacific countries to get better access to innovative healthcare services and augment Korea\u2019s bio-health innovation. Samsung looks cheerful about the deal inked to support AZ\u2019s dream to expand through its large-scale commercial manufacturing capabilities to develop drug substances as well as products.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gyroscope-s-gene-therapy-for-dry-amd-gt005-receives-usfda-fast-track-designation\"><span class=\"ez-toc-section\" id=\"Gyroscopes_gene_therapy_for_Dry_AMD_GT005_receives_USFDA_Fast_Track_Designation\"><\/span><strong>Gyroscope\u2019s gene therapy for Dry AMD, GT005, receives USFDA Fast Track Designation&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Gyroscope Therapeutics, <\/strong>a company committed to developing gene therapies for retinal disorders, has launched the first-ever gene therapy clinical trial for <strong>GT005 <\/strong>in patients with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-age-macular-degeneration-pipeline-insight\" class=\"ek-link\">dry-form of age-related macular degeneration (Dry AMD)<\/a><\/strong>.\u00a0<\/p>\n\n\n\n<p>The company announced the clearance of the Fast Track Designation by the USFDA of GT005, an investigational one-time AAV-based gene therapy, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/geographic-atrophy-ga-epidemiology-forecast\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>geographic atrophy<\/strong> <\/a>&#8211; <em>for patients with specific mutations in the Complement Factor I (CFI) gene and lower levels of the CFI protein in the blood- <\/em>secondary to Dry AMD. Last month, the company announced the initiation of Phase II clinical trial EXPLORE for geographic atrophy (GA).&nbsp;<\/p>\n\n\n\n<p>AMD is the most common cause of vision loss in the elderly, and the present AMD treatment market holds limited treatment options, and this is why several of the patients suffering from Dry AMD progresses to develop a <a href=\"https:\/\/www.delveinsight.com\/blog\/wet-age-related-macular-degeneration\/\" target=\"_blank\" rel=\"noreferrer noopener\">wet form of the age-related macular degeneration<\/a>. Thus, the company believes in exploring the options gene therapy has to offer as well as early preventive interventions to stop or even slow down the progression of the disease.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-with-soaring-interest-in-inflammation-roche-acquires-inflazome-for-380-m\"><span class=\"ez-toc-section\" id=\"With_soaring_interest_in_inflammation_Roche_acquires_Inflazome_for_E380_M\"><\/span><strong>With soaring interest in inflammation, Roche acquires Inflazome for \u20ac380 M<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Roche<\/strong>, in a bid to get its hands on Inzomelid, and other treatments for inflammatory diseases, has shelled out \u20ac380 Million or about USD 451 Million upfront and has acquired&nbsp; Dublin-based <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/boehringer-inflammasome-to-advance-retinal-disease-pipeline\/\" target=\"_blank\" rel=\"noreferrer noopener\">Inflazome<\/a><\/strong>.&nbsp;<\/p>\n\n\n\n<p>The Swiss-giant had also acquired US biotech, <strong>Jecure Therapeutics<\/strong>, last year, who deals in drug development and discovery for severe inflammatory diseases, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\" target=\"_blank\" rel=\"noreferrer noopener\">non-alcoholic steatohepatitis (NASH)<\/a> and liver fibrosis.<\/p>\n\n\n\n<p>With the recent decision to nab Inflazome, it appears Roche\u2019s interest to expand in the inflammatory disease market has piqued. The clearance of Orphan Drug Designation for Inzomelid by the USFDA two months back for Cryopyrin-Associated Periodic Syndrome (CAPS) might have also influenced the company\u2019s decision to go forward with the acquisition.&nbsp;<\/p>\n\n\n\n<p>The present deal adds small molecule drugs designed to target inflammasomes, specifically NLRP3 inflammasome, to Roche\u2019s existing vast and diverse portfolio.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbott-s-next-gen-mitraclip4-heart-valve-repair-device-nabs-eu-approval\"><span class=\"ez-toc-section\" id=\"Abbotts_next-gen_MitraClip4_heart_valve_repair_device_nabs_EU_approval\"><\/span><strong>Abbott\u2019s next-gen MitraClip4 heart valve repair device nabs EU approval<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Abbott <\/strong>announced a European approval for its fourth-generation MitraClip device, known as <strong>MitraClip G4<\/strong>, for mitral regurgitation. Last year, the company had received the US FDA approval for its device.<\/p>\n\n\n\n<p>The latest version of the device proffers additional enhancements to MitraClip&#8217;s first-of-its-kind clip-based technology.&nbsp; The device commercially debuted from the European market in 2008 and entered the US market in 2013.&nbsp;<\/p>\n\n\n\n<p>The company has an edge in the market for its device has been available for more than 15 years, and is the first and only effective and safe transcatheter <a href=\"https:\/\/www.delveinsight.com\/report-store\/mitral-valve-insufficiency-market\" target=\"_blank\" rel=\"noreferrer noopener\">mitral valve<\/a> therapy.<\/p>\n\n\n\n<p>This marks the fourth consecutive approval since its inception after the introduction of G2, and G3 to support patient care. The G4 device comes with additional sizes and two wider clip options along with the four clip sizes to offer a variety of treatment options that can suit patients&#8217; unique mitral valve anatomy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-illumina-to-pay-a-total-of-usd-8-bn-to-reacquire-its-former-spinout-grail\"><span class=\"ez-toc-section\" id=\"Illumina_to_pay_a_total_of_USD_8_Bn_to_reacquire_its_former_spinout_Grail\"><\/span><strong>Illumina to pay a total of USD 8 Bn to reacquire its former spinout Grail<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Illumina, <\/strong>a leading manufacturer of devices for DNA sequencing and array-based technologies, announced the acquisition of <strong>GRAIL<\/strong>, a healthcare firm developing innovative technologies for early cancer detection, for USD 8 Billion.&nbsp;<\/p>\n\n\n\n<p>Grail was put onto the map in 2016 in the spin-out with Illumina investing a hefty sum of USD 100 Million. Over the years, Grail has developed technologies that can detect several forms of <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\" target=\"_blank\" rel=\"noreferrer noopener\">cancers<\/a> early, shifting the power into the patient\u2019s side, with the latest being a simple blood test that can expose 50 different types of cancers at the earlier stages.&nbsp;<\/p>\n\n\n\n<p>Biotech has become a hot topic now, and several companies are trying their best to have a share of the booming market size. A result of spin-out, Grail is now being spun-back, also shows the unpredictable nature of the biotech industry.&nbsp;<\/p>\n\n\n\n<p>Nevertheless, the acquisition will surely give Illumina, the access to Grail\u2019s best-in-class, proprietary tests in each of the major oncology testing application areas that, undisputedly, open the doors to a myriad of opportunities for the company.&nbsp;&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca&nbsp; Samsung Biologics announced the conclusion of a long-term supply deal with AstraZeneca worth USD 330.8 Million.&nbsp; AZ has made several headlines the past few months, forming a slew of deals to manufacture and supply its products. Here, the company plans to leverage Samsung\u2019s expertise [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10776,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":3,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1271,16689,1261,712,639],"industry":[17225],"therapeutic_areas":[17245,17228],"class_list":["post-10772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight-pharma-news","tag-healthcare-news","tag-pharma-consulting","tag-pharma-industry","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome&#039;s Buyout; &amp; much more<\/title>\n<meta name=\"description\" content=\"Samsung\/AZ Deal; Fast Track Designation to Gyroscope\u2019s Dry AMD Gene Therapy; Inflazome&#039;s Buyout, Abbott\u2019s MitraClip4; Illumina-Grail Deal\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome&#039;s Buyout; &amp; much more\" \/>\n<meta property=\"og:description\" content=\"Samsung\/AZ Deal; Fast Track Designation to Gyroscope\u2019s Dry AMD Gene Therapy; Inflazome&#039;s Buyout, Abbott\u2019s MitraClip4; Illumina-Grail Deal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-22T10:10:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T06:29:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/22153422\/News-Sep-22.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome's Buyout; & much more","description":"Samsung\/AZ Deal; Fast Track Designation to Gyroscope\u2019s Dry AMD Gene Therapy; Inflazome's Buyout, Abbott\u2019s MitraClip4; Illumina-Grail Deal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina","og_locale":"en_US","og_type":"article","og_title":"Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome's Buyout; & much more","og_description":"Samsung\/AZ Deal; Fast Track Designation to Gyroscope\u2019s Dry AMD Gene Therapy; Inflazome's Buyout, Abbott\u2019s MitraClip4; Illumina-Grail Deal","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-09-22T10:10:30+00:00","article_modified_time":"2023-04-04T06:29:12+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/22153422\/News-Sep-22.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina","name":"Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome's Buyout; & much more","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/22153422\/News-Sep-22.jpg","datePublished":"2020-09-22T10:10:30+00:00","dateModified":"2023-04-04T06:29:12+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Samsung\/AZ Deal; Fast Track Designation to Gyroscope\u2019s Dry AMD Gene Therapy; Inflazome's Buyout, Abbott\u2019s MitraClip4; Illumina-Grail Deal","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-samsung-az-roche-gyroscope-abbott-illumina#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/22153422\/News-Sep-22.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/22153422\/News-Sep-22.jpg","width":772,"height":482,"caption":"Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome's Buyout; Abbott's MitraClip4; Grail Buyback"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/09\/22153422\/News-Sep-22-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Healthcare News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">Healthcare News<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Sep 22, 2020","modified":"Updated on Apr 4, 2023"},"absolute_dates_time":{"created":"Posted on Sep 22, 2020 3:40 pm","modified":"Updated on Apr 4, 2023 11:59 am"},"featured_img_caption":"Samsung\/AZ Deal; Gyroscope\u2019s GT005; Inflazome's Buyout; Abbott's MitraClip4; Grail Buyback","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10772"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10772\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10776"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10772"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10772"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}